Cancer Vaccine Breakthrough: Personalized mRNA Immunotherapy Achieves 78% Remission Rate in Landmark Phase 3 Clinical Trials
Tailored precisely to a patient’s unique tumor biopsy in under six weeks, the treatment trains the human immune system to hunt and destroy malignant cells permanently.